Feed AVTX
AV

Avalo Therapeutics, Inc. AVTX · NASDAQ

$12.26 -0.81% (-$0.10)

Market cap
$657.5M
Enterprise value
$572.4M
P/E
-
Forward P/E
-
PEG
-
P/S
11,144.1x
P/FCF
-
EV/EBITDA
-
ROIC
-19.5%
Gross margin
-16,861.0%
Net margin
-170,056.0%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.79
Free float
89.6%

About the company

Avalo Therapeutics is an American biopharmaceutical company focused on developing medicines for the treatment of cancer and autoimmune diseases. The company specializes in utilizing innovative therapeutic approaches, including immunotherapy and targeted therapy, to identify and treat various types of cancer. Their research and development efforts are aimed at discovering new drug compounds and therapeutic methods that could improve the lives of patients and bring new hope to the field of cancer treatment. Avalo Therapeutics shares could be an interesting choice for investors looking for opportunities in the biotechnology sector and drug development for cancer.

Sector

Healthcare

Industry

Biotechnology

CEO

Garry A. Neil

Employees

33

Headquarters

Wayne

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.